T2 Biosystems Receives FDA Clearance To Market T2Candida Panel For Pediatric Patients, The Only Test Detecting Sepsis-Causing Candida Species Directly From Blood In 3-5 Hours Without Blood Culture; Panel Detects Five Candida Species Responsible For 95% Of U.S. Bloodstream Infections
Portfolio Pulse from Benzinga Newsdesk
T2 Biosystems has received FDA clearance to market its T2Candida Panel for pediatric patients. This is the only test that can detect sepsis-causing Candida species directly from blood in 3-5 hours without the need for a blood culture. The panel can detect five Candida species responsible for 95% of U.S. bloodstream infections.
September 16, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
T2 Biosystems' FDA clearance for the T2Candida Panel is a significant milestone, potentially boosting its market position. The panel's unique ability to detect Candida species quickly without blood culture could drive demand and revenue growth.
The FDA clearance allows T2 Biosystems to market a unique product that addresses a critical need in healthcare, potentially increasing its market share and revenues. The ability to detect Candida species quickly is a competitive advantage.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100